423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway.
Introduction
Glioblastoma multiforme (GBM) is one of the most common primary malignant brain tumors, with highly aggressive, invasive, and neurologically destructive characters. GBM has high mortality and morbidity: Despite a combination of approaches, including surgery, radiation therapy, and chemotherapy, the median 5-year survival rate of patients is less than 5%. 1 To date, studies have reported that the main cause of mortality in GBM patients is recurrence, and glioma stem cells (GSCs) are enriched in GBM compared with other types of gliomas. Thus, it is considered that the presence of GSCs-a subpopulation of highly tumorigenic glioma cells characterized by indefinite proliferation, self-renewal, and drug resistance capabilities-is an important factor for GBM recurrence. GSCs are proven to be major contributors to glioma progression and play key roles in therapy resistance. Therefore, it is essential to find novel and effective anti-GSC therapeutic approaches.
MicroRNAs (miRNAs) are small, endogenous noncoding RNAs that have recently been found to function as tumor suppressors or oncogenes involved in tumor pathogenesis, and related miRNA pathways are reportedly involved in stem cell proliferation and apoptosis. Morgado et al. 2 showed that miR-145 regulates neural stem cell differentiation through the Sox2-Lin28/let-7 signaling pathway and that miR-145-mediated modulation of the Sox2-Lin28/let-7 network is crucial for neurogenesis progression. Zheng et al. 3 reported that overexpression of miR-186 inhibits the proliferation, migration, and invasion of GSCs and promotes apoptosis, and Esposito et al. 4 found that combining miR-137 and anti-miR-10b could prevent GSC expansion. Recently, the "Pharmaco-miR" concept has been put forth through miRNA pharmacogenomics, which is defined as the study of miRNAs and polymorphisms affecting miRNA function to predict drug behavior and improve drug efficacy. Prospective studies have demonstrated that miRNAs play a central role as a novel regulatory layer affecting drug metabolism and targets. [5] [6] [7] Chen et al. 8 reported that miR-125b is upregulated in temozolomide (TMZ)-resistant cells and that inhibition of this miRNA resulted in a marked increase in TMZinduced cytotoxicity and apoptosis and a subsequent decrease in TMZ resistance in GSCs. Shi et al. 9 also showed that miR-125b functions in the development of GSC resistance to TMZ and that inhibiting miR-125b enhances GSC sensitivity to TMZ with respect to cell invasion. In addition, Zhang et al. 10 found that neither miR-21 inhibitor nor TMZ induced GSC apoptosis but that miR-21 inhibitor combined with TMZ significantly enhanced apoptosis in GSCs.
We recently identified a miRNA named miR-423-5p as being overexpressed in GBMs. 11 Our data showed miR-423-5p to be increased in World Health Organization (WHO)-III and IV gliomas but not in WHO-II gliomas; it was also overexpressed in the corresponding primary GSCs. Downregulation of miR-423-5p expression resulted in decreased cell proliferation but not in cell apoptosis. These data demonstrate that miR-423-5p functions as an oncogene in GSCs. Apigenin is a bioflavonoid found in citrus, and similar to other flavonoids, it possesses antioxidant, anti-inflammatory, and anti-tumor properties. Recent studies have shown that apigenin can inhibit U87 glioma cell growth and U251 GSC proliferation. 12, 13 However, in this study, we found that apigenin has no effect on GSC apoptosis. Based on "Pharmaco-miR," we further demonstrated that the combination of miR-423-5p knockdown and apigenin had a marked additive effect on inhibiting proliferation and increasing apoptosis in GSCs. This is the first report of the combined functions and mechanisms of miR-423-5p knockdown and apigenin in GSCs. This study focused on the cell apoptotic inducing effect of miR-423-5p knockdown and apigenin on GSCs and its related mechanism.
Materials and methods

Primary glioblastoma cell cultures
Human glioma tissues were collected from adult patients after obtaining informed consent. During surgery, fresh samples of glioma tissues were placed in sterile saline. After removing any blood present, the tissue was washed with phosphate-buffered saline (PBS, pH 7.40). The tissue was then cut and passed through a 200 mesh screen. Serumfree Dulbecco's Modified Eagle's Medium (DMEM) was added and the sample was centrifuged for 5 min at 2000 r/ min. The supernatant was removed and 0.25% trypsin was added for digestion. The sample was incubated for 15 min at room temperature and DMEM containing 10% fetal bovine serum (FBS) was added to terminate the reaction. After centrifugation, the supernatant was discarded and DMEM culture containing 10% fetal calf serum was added. The sample was again centrifuged and the supernatant was discarded. The cell suspension was added to a culture bottle with 2% DMEM/F-12 and incubated for a week, after which the medium was replaced with DMEM/F-12 medium containing 10% FBS. The cells were cultured at 37°C in a 5% CO 2 incubator. After reaching 70%-80% confluence, adherent cells were digested and passaged. Glial origin was confirmed by morphology and staining with an anti-glial fibrillary acidic protein (GFAP) monoclonal antibody (mAb) clone 6F2 (Dako, Glostrup, Denmark). 14 
Magnetic cell separation of CD133-positive cells
Cells were collected and added to 1% FBS-RPMI, and the cell suspension was pre-cooled at 4°C and mixed with 50 µL CD133 antibody beads (Miltenyi Biotec, Bergisch Gladbach, Germany). After cooling again at 4°C, the cell suspension was placed in a magnetic particle separator for 3 min. The CD133-positive cell fraction was collected and centrifuged at 2000 r/min for 5 min, and the supernatant was removed. The CD133-positive cells were collected and washed twice with PBS. After centrifugation at 2000 r/ min for 5 min, the CD133-positive cells were cultured in neural stem cell culture medium including DMEM/F-12 supplemented with 20 ng/mL each of human recombinant epidermal growth factor, human recombinant basic fibroblast growth factor (both from R&D Systems, Minneapolis, MN, USA), and human leukemia inhibitory factor (Chemicon, Millipore(R), USA), in addition to 2% B27 (Life Technologies, Darmstadt, Germany).
Cell growth assay
To assess the effects of miR-423-5p and/or apigenin on the growth of CD133-positive GSCs, these cells were plated at 5 × 10 3 cells per well in 96-well plates, with six replicate wells at the indicated concentrations of miR-423-5p inhibitor and/or apigenin. To analyze cell proliferation at certain time points after transfection, the MTT assay (3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide) was performed as described previously. 15 Hoechst 33258 staining for morphological analysis of apoptosis Cells were cultured in six-well plates. After the indicated treatment, the cells were washed twice with PBS and fixed with 4% paraformaldehyde for 1 h. The PBS was removed and 50 µM Hoechst 33258 staining solution was added for 10 min. Apoptotic morphological changes were detected under a fluorescence microscope.
Mitochondrial membrane potential analysis
Mitochondria play an important role in inducing apoptosis, and decreases in mitochondrial membrane potential (ΔΨm) are an early hallmark of apoptosis. JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-dazolylcarbocya-nine iodide) is a probe that is used for detecting mitochondrial membrane potential. It exists as a monomer when the mitochondrial membrane potential is low, and cells exhibit green fluorescence. However, a dimer forms when the mitochondrial membrane potential increases, and the cells exhibit red fluorescence. To measure the mitochondrial membrane potential for apoptosis analysis, JC-1 staining was performed using Accuri's JC-1 Mitochondrial Potential Assay Kit (Invitrogen, Carlsbad, CA, USA) according to the instructions.
Annexin V/PI apoptosis assays
Cells were digested with trypsin without ethylenediaminetetraacetic acid (EDTA) and centrifuged at 300g for 5 min at 4°C. The cells were washed twice with pre-cooled PBS, with centrifugation at 300g at 4°C for 5 min each. Binding buffer (100 µL) was added to the suspension cells; 5 µL Annexin V-FITC and 5 µL propidium iodide (PI) staining solution were then added, followed by gentle mixing. The samples were incubated at room temperature for 10 min in dark. Then, the binding buffer (400 µL) was added and mixed well. The samples were evaluated for apoptosis percentages using flow cytometry.
Western blot analysis
After treatment with miR-423-5p inhibitor and/or apigenin, cells were collected, and proteins were isolated using lysis buffer (Bio-Rad Laboratories, Richmond, CA, USA). After electrophoresis and transfer to a membrane, the proteins were incubated with primary antibodies against Bax, Bcl-2, cytochrome c, and Apaf-1 (used at a 1/200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA) for 1.5 h at 37°C in a water bath. The membranes were then incubated with secondary antibodies for 1.5 h at 37°C in a water bath. Bands were detected using enhanced chemiluminescence (Amersham Life Science, Arlington Heights, IL, USA). An anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) antibody (1/2000, Santa Cruz Biotechnology) was used for equal loading of the gel.
Caspase-3 activity assay
A caspase-3 activity kit (Beyotime Institute of Biotechnology, Haimen, China) was used to detect caspase-3 activity. Adherent cells were digested with trypsin, and collected and centrifuged at 600g at 4°C for 5 min. The supernatant was carefully removed and the cells were washed once with PBS. After centrifugation, the supernatant was removed. Each of the 2 million cells were added to 100 µL of lysate added lysate, suspend the precipitation and cracking on the ice bath for 15 min. The sample was centrifuged for 10-15 min at 4°C at 16,000g-20,000g and the supernatant was transferred to pre-cooled centrifuge tubes. After adding Ac-DEVD-pNA (2 mM) and mixing, the sample was incubated at 37°C for 60-120 min. Samples were measured using an enzyme-linked immunosorbent assay (ELISA) reader at an absorbance of 405 nm.
Statistical analysis
All tests were performed using SPSS Graduate Pack 19.0 statistical software (SPSS, Chicago, IL, USA). Descriptive statistics, including the mean and standard error (SE), and one-way analysis of variance (ANOVA) were used to determine significant differences. A value of p < 0.05 was considered statistically significant.
Results
Evaluation of miR-423-5p expression in human glioma tissues and corresponding GSCs
Li et al. 11 showed that miR-423-5p is highly expressed in human glioma tissues and that its expression is positively correlated with the grade of glioma. However, we found that miR-423-5p exhibited different expression patterns in all glioma grades. In this study, we collected normal and glioma tissue samples, including 7 normal brain tissues, 10 cases of grade II glioma, 11 cases of grade III glioma, and 12 cases of grade IV glioma to investigate miR-423-5p expression in different grades of glioma. As shown in Figure 1(a) , miR-423-5p was expressed in a low level in normal brain tissues and was not obviously overexpressed in grade II gliomas. In contrast, miR-423-5p expression was much higher in grade II and III gliomas compared with normal and grade II glioma tissues (p < 0.05; Figure 1(b) ). Regardless, statistical analysis showed no significant differences for levels of miR-423-5p between grade III and IV glioma tissues (p > 0.05; Figure 1(b) ).
The level of miR-423-5p expression in GSCs is unknown to date. To confirm that GSCs are more tumorigenic in vivo than non-GSCs, 1 × 10 7 /mL of GSCs or non-GSCs were directly injected subcutaneously into the flanks of nude mice; after 30 days, the tumor volume resulting from GSC injection was greater than that for non-GSCs (Figure 1(c) ). We cultured primary GSCs from WHO-IV glioma tissues identified by CD133 and Nestin expression. Our data showed higher expression of miR-423-5p in GSCs than in corresponding WHO-IV glioma tissues (Figure 1(d) ).
Evaluation of miR-423-5p inhibitor or apigenin regarding GSC viability and apoptosis
To measure the effects of miR-423-5p knockdown on the proliferation of primary GSCs, these cells were transfected with miR-423-5p inhibitor. As shown in Figure 2(a) , miR-423-5p expression in GSCs was decreased by, approximately, 96.3% at 48 h after transfection in the miR-423-5p inhibitor model compared with the control (p < 0.05). The MTT assay was then used to detect the in vitro growth ability of GSCs. As shown in Figure 2 (b), GSC growth rates with miR-423-5p inhibitor transfection were, approximately, 11.32 ± 1.73%, 16.39 ± 2.37%, and 19.31 ± 3.16% at 24, 48, and, 72 h, respectively. Furthermore, Hoechst 33258 staining was used to observe the morphological features of apoptosis after miR-423-5p knockdown, and we found no significant differences with regard to the amount of apoptotic death in the miR-423-5p inhibitor group compared with the control group (Figure 2(c) ). Figure 2(d) shows that the proliferation ability of GSCs was inhibited by different concentrations of apigenin at 24, 48, or 72 h of treatment, and the inhibition effect was time and dose dependent. Moreover, no obvious morphological features of apoptosis were observed by Hoechst 33258 staining after 20 or 40 µM apigenin treatment for 48 h (Figure 2(e) ).
miR-423-5p inhibitor and apigenin had additive effects on inhibiting GSC proliferation and promoting apoptosis
As shown in Figure 3(a) , pre-treatment with miR-423-5p inhibitor and 10, 20, or 40 µM apigenin for 48 h increased the growth inhibition rate in GSCs, and the increased inhibition was positively correlated with the concentration of apigenin. After combined treatment for 48 h, morphological features of apoptosis were also observed in the miR-423-5p inhibitor + apigenin group by Hoechst 33258 staining (Figure 3(b) ), and increases in apoptosis were observed with increasing apigenin concentration. Therefore, we speculate that knockdown of miR-423-5p actually increased the sensitivity of GSCs to apigenin. Flow cytometry analysis revealed apoptosis rates of 7.3%, 13.6%, and 17.6%, respectively (Figure 3(c) ).
Mitochondrial membrane potential was downregulated by apigenin treatment
JC-1 is an ideal fluorescent probe which is widely used for detecting mitochondrial membrane potential (ΔΨm) in cells, tissues, or purified fractions, and a decrease in mitochondrial membrane potential is a hallmark of the early stage of apoptosis. JC-1 aggregates in the mitochondrial matrix when the mitochondrial membrane potential is high, forming polymers (J-aggregates) that produce red fluorescence. When the mitochondrial membrane potential is low, JC-1 cannot aggregate in the mitochondrial matrix and exists as a monomer that produces green fluorescence. Therefore, this probe is very convenient for detecting changes in mitochondrial membrane potential based on fluorescent color changes, which can be expressed as a detection index of early apoptotic cells. As shown in Figure 4 , the mitochondria membrane potentials of GSCs treated with miR-423-5p inhibitor combined with 20 or 40 µg/mL apigenin were significantly reduced compared with miR-423-5p inhibitor or 20 or 40 µg/mL apigenin alone. Therefore, we hypothesized that this could reflect apoptosis induced by the combined treatment of miR-423-5p inhibitor and apigenin in association with the mitochondrial pathway.
miR-423-5p inhibitor + apigenin induced cell apoptosis by activating Bax/Bcl-2-caspase-3 signaling
Liu et al. 16 showed that expression of Bcl-2 family proteins has an important role in GSC apoptosis; they also showed that miR-21 inhibitor sensitized U251 stem cells to TMZ by regulating the Bax/Bcl-2 ratio. Bax functions as an apoptotic activator in GSCs, and this protein is reported to interact with and increase the opening of the mitochondrial voltage-dependent anion channel (VDAC), which leads to loss in membrane potential and the release of cytochrome c. 17 Bcl-2 acts as an anti-apoptotic regulator in GSCs, and Qiu et al. 18 showed that levels of Bcl-2 expression were higher in GSCs and that its expression was related to glioma malignancy. As an anti-apoptotic gene, expression of Bcl-2 coincides with the pivotal biological features of GSCs. High Bcl-2 expression allows GSCs to evade apoptosis, and therapies targeting Bcl-2 induce apoptosis in GSCs. Zhang et al. 19 also showed that epigallocatechin gallate (EGCG) induced apoptosis in U87 GSCs by downregulating Bcl-2 and cleaving poly (ADP-ribose) polymerase (PARP). To confirm that the synergistic anti-cancer mechanisms of miR-423-5p inhibitor + apigenin in GSCs relies on Bax and Bcl-2 alterations, the levels of Bax and Bcl-2 were measured after miR-423-5p inhibitor + apigenin treatment by western blot analysis. Our data showed that combined treatment of miR-423-5p inhibitor + 20 µg/mL apigenin significantly increased Bax expression and decreased Bcl-2 expression compared with miR-423-5p inhibitor or apigenin alone 
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(p < 0.05; Figure 5(a) ). Furthermore, we examined the downstream signaling pathway of the Bcl-2 family, including cytochrome c, Apaf-1, and caspase-3. As shown in Figure 5(b) , expression of cytochrome c and Apaf-1 in GSCs was significantly increased after miR-423-5p inhibitor + apigenin treatment compared with miR-423-5p inhibitor or apigenin alone, whereas treatment with miR-423-5p inhibitor or apigenin alone did not result in a significant increase in cytochrome c and Apaf-1 compared with the control group. Caspase-3 activity was measured using a caspase-3 activity kit, and our data showed an obvious increase in caspase-3 activity in the miR-423-5p inhibitor + apigenin group compared with groups treated with miR-423-5p inhibitor or apigenin alone ( Figure 5(c) ). These results suggest that the combined treatment of GSCs with miR-423-5p inhibitor and apigenin activates apoptosis-related proteins in the mitochondrial pathway.
Discussion
At present, cancer drug resistance is considered an important factor contributing to the failure of glioma treatment. The presence of GSCs is thought to be responsible for chemotherapy resistance. Similar to normal stem cells, GSCs are capable of self-renewal, differentiation, unlimited proliferation, and resistance to conventional therapy, including radiotherapy and chemotherapy, due to higher expression of multidrug transporters. 20 Recent studies have shown that targeting certain miRNAs can successfully interfere with the above-mentioned properties of GSCs and enhance the sensitivity of GSCs to chemotherapeutic drugs. Using human glioblastoma stem cells, Wu et al. 21 showed that miR-218-5p could inhibit the stem cell properties of glioma. Wang et al. 22 found that miR-608 expression was significantly downregulated in GSCs and that miR-608 overexpression could significantly attenuate GSC proliferation, migration, and invasion, and induce apoptosis. Liu et al. 23 reported that miR-143 plays a critical role in the anti-tumor activity of shikonin in GSCs, with miR-143 upregulation significantly enhancing the inhibitory effect of shikonin on GSC growth.
In this study, we focused on another miRNA, miR-423-5p, the dysfunction of which has recently been found in some cancers. Fang et al. 24 found that miR-423-5p is downregulated in the plasma of colorectal cancer (CRC) cells and that it could serve as a potential biomarker for colorectal carcinoma. Stiuso et al. 25 showed that miR-423-5p promotes autophagy in hepatocarcinoma cells, and miR-423-5p was also found to regulate cell proliferation and invasion in gastric cancer cells. 26 In gliomas, miR-423-5p is reportedly overexpressed in Chinese primary glioblastomas 27 and contributes to the malignant phenotype as well as TMZ chemoresistance. 11 However, the expression and function of miR-423-5p in GSCs have remained unknown. In this study, we confirmed that miR-423-5p is overexpressed in primary GSCs compared with corresponding primary glioma tissues. Knockdown of miR-423-5p in primary GSCs could inhibit proliferation but not apoptosis and could enhance the sensitivity of cancer cells to chemotherapeutic drugs, similar to other miR-NAs. Our data also demonstrated that knockdown of miR-423-5p could effectively enhance the anti-GSC effects of apigenin, including increased growth inhibition and apoptosis.
Detection of the mitochondrial membrane potential (ΔΨm) in this study showed that combined treatment of miR-423-5p inhibitor and apigenin significantly decreased the ΔΨm in GSCs, suggesting that the synergistic anti-cancer mechanisms of miR-423-5p inhibitor + apigenin involve a mitochondria-related signaling pathway. The mitochondrial apoptosis pathway is considered to be the major target by which anti-cancer drugs induce apoptosis in many cancer cells, causing DNA damage, influencing the proteolysis or dephosphorylation of apoptosis-promoting proteins, activating caspases, and leading to the characteristic changes of apoptosis. 28 In this study, Hoechst 33258 staining revealed the characteristic changes of apoptosis in the nucleus of GSCs after miR-423-5p inhibitor + apigenin treatment. The anti-apoptotic protein of Bcl-2 was detected and found to be decreased, whereas the pro-apoptotic protein Bax was increased with the combined treatment. The Bcl-2 family regulates the release of cytochrome c from mitochondria into the cytosol, interacts with Apaf-1, and leads to caspase activation in the apoptosome, which is crucial for the induction of apoptosis. To further verify that the higher apoptosis rate in GSCs induced by miR-423-5p inhibitor + apigenin treatment was achieved through the mitochondrial pathway, we detected the expression of cytochrome c, Apaf-1, and caspase-3. Western blot data confirmed that the expression levels of apoptosis-related proteins, cytochrome c and Apaf-1, were increased after the combined treatment, and caspase-3 activity was also confirmed to be upregulated.
In conclusion, these results indicate that either miR-423-5p inhibitor or apigenin can inhibit growth but not apoptosis in GSCs. However, combined treatment of miR-423-5p inhibitor + apigenin exerts an additive effect, inducing GSC apoptosis primarily through a mitochondria-dependent pathway.
